The pandemic-era bonanza is firmly in the rearview mirror at BioNTech, replaced by a searing quarterly loss and a sweeping overhaul that merges deep cost cuts with a revamped incentive structure for top executives. The Mainz-based company is burning through cash on its oncology pipeline while simultaneously shuttering production sites and tying management pay to relative stock performance — a two-pronged strategy designed to keep investors onside during a high-stakes transition.
Between January and March, revenues collapsed to €118.1 million, down from the billions seen during Covid-19 vaccine sales. The net loss widened to €531.9 million, driven by ballooning research and development spending. Despite the red ink, the balance sheet remains fortified with €16.8 billion in liquid assets, and the board is standing by its full-year revenue guidance of €2.0 billion to €2.3 billion.
To fund the costly oncology push, management is slashing operational expenses. BioNTech plans to close manufacturing facilities in Marburg, Idar-Oberstein, and Singapore, eliminating roughly 1,860 jobs. Once the restructuring is complete, the company expects annual savings of €500 million. Those freed-up resources are being redirected straight into clinical development.
The oncology pipeline is the centerpiece of the turnaround. In the first quarter alone, BioNTech and Bristol Myers Squibb launched five registration studies for the antibody Pumitamig. A new collaboration with Boehringer Ingelheim targets lung cancer, while a drug for cervical cancer, developed jointly with DualityBio, is slated for a regulatory filing later this year. Separately, founders Ugur Şahin and Özlem Türeci are spinning off the next generation of mRNA technology into an independent entity.
Should investors sell immediately? Or is it worth buying BioNTech?
Alongside the operational shake-up, BioNTech has introduced performance-linked compensation for its leadership team. U.S. filings on May 13 revealed new equity awards for top managers. CFO Ramon Zapata Gomez received 15,103 performance share units and 18,879 stock options. COO Sierk Poetting and Commercial chief Annemarie Hanekamp each obtained 10,069 PSUs and 12,586 options, identical to the package granted to manager Ryan James Timothy Patrick. The options carry an exercise price of €89.38, vest in equal annual tranches over four years, and expire on May 12, 2036. Crucially, the PSUs are tied to BioNTech’s stock performance relative to the Nasdaq Biotechnology Index, ensuring that variable pay depends on outperforming the peer group rather than just the absolute share price.
To back up the new incentive scheme, BioNTech announced a share buyback program authorizing up to $1 billion in American Depositary Shares. The repurchases, which began on May 7 and run through May 6, 2027, will be used partly to fulfill obligations arising from equity-based compensation programs. The board can settle awards in ordinary shares, ADS, or cash, and a technical clause allows adjustments if the ADS price exceeds 800% of the original exercise price.
On the stock market, the transformation has yet to win over investors. The shares are trading around €78.70, roughly 5% below their start-of-year level and stuck beneath both the 50-day moving average of €82.16 and the 200-day line. With six major data readouts from advanced pipeline programs expected over the rest of 2026 — including updates on antibody-drug conjugates and mRNA cancer immunotherapies — the coming months will determine whether BioNTech’s radical pivot can deliver the proof points the market is demanding. In the meantime, the company is also preparing variant-adapted Covid-19 vaccines for the 2026/2027 respiratory season, a reminder that the old cash cow still plays a supporting role.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from May 14 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 14.
BioNTech: Buy or sell? Read more here...
